PB 100 of 2024

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (October Update) Instrument 2024

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the National Health Act 1953.

Dated 27 September 2024

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024
(PB 31 of 2024) 2

1.                Name

1.            This instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (October Update) Instrument 2024
2.            This instrument may also be cited as PB 100 of 2024.

1.                Commencement

1.            Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1.             Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1.                Authority

This instrument is made under subsection 100(2) of the National Health Act 1953.

1.                Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)

1.            Schedule 1, Part 1, entry for Bendamustine in each of the forms: Powder for injection containing bendamustine hydrochloride 25 mg; and Powder for injection containing bendamustine hydrochloride 100 mg

omit:

1.            Schedule 1, Part 1, after entry for Bevacizumab in the form Solution for I.V. infusion 100 mg in 4 mL [Brand: Mvasi]

insert:

1.            Schedule 1, Part 1, after entry for Bevacizumab in the form Solution for I.V. infusion 400 mg in 16 mL [Brand: Mvasi]

insert:

1.            Schedule 1, Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 100 mg in 20 mL

omit:

1.            Schedule 1, Part 1, entry for Pembrolizumab

omit from the column headed “Circumstances”: C14405

1.            Schedule 1, Part 2, entry for Pembrolizumab [Maximum Amount: 400 mg; Number of Repeats: 6]

omit from the column headed “Purposes”: P14405

1.            Schedule 2, after entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg [Brand: Ondansetron ODT-DRLA]

insert:

1.            Schedule 3, Part 1, omit entry for Circumstances Code “C14405”